PGL-034

PGL-034 is a small molecule benzothiazole derivative identified as a potent inhibitor of huntingtin (HTT) protein aggregation. Developed through a collaboration between PsychoGenics Inc. and the Max Planck Institute for Molecular Genetics, the compound was discovered using an automated filter retardation assay that screened a library of approximately 184,000 small molecules. PGL-034 is structurally related to riluzole and has demonstrated the ability to dose-dependently suppress the self-assembly of huntingtin exon 1 protein into insoluble fibrillar aggregates in vitro. Furthermore, in vivo studies in Huntington's disease models have shown that PGL-034 can significantly inhibit the formation of these toxic protein aggregates, suggesting its potential as a therapeutic strategy for Huntington's disease and other polyglutamine repeat disorders.

Other names

2-amino-4,7-dimethyl-benzothiazol-6-ol2-amino-4,7-dimethyl-1,3-benzothiazol-6-ol